Research status of inhaler triple therapy for chronic obstructive pulmonary disease

Jing-zi LI,Ying ZHOU,Yi-min CUI
DOI: https://doi.org/10.13699/j.cnki.1001-6821.2017.21.029
2017-01-01
Abstract:Chronic obstructive pulmonary disease (COPD)is a common chronic respiratory system disease that could not be cured,and the prevalence and cost of which is high.Triple inhaled therapy of inhaled corticosteroid/long-acting β2-agonist/long-acting bronchodilators (ICS/ LABA/LAMA) improves lung function,symptoms and health status and reduces exacerbations compared to ICS/LABA or LAMA monotherapy.Single-inhaler combination of ICS/LABA/LAMA can improve patient compliance and efficacy.However,it's hard to change the specific dose of one single compound through a single-inhaler combination of three compounds.This review aimed to provide information for the rational clinical use of the single inhaler of triple therapy in the future.
What problem does this paper attempt to address?